Abstract
A Hepatitis C clinical trial program for patients infected with Hepatitis C virus of genotype I demonstrated that the sustained virologic response rate is higher with 48 weeks of Ribavirin in combination with Interferon (I/R) than with 48 weeks of interferon and placebo (UP). The intent-to-treat (ITT) response rate for the I/R group is 29%, versus 9% for the UP group. However, since not all patients completed their treatment, it is likely that the benefit would have been greater if all the patients had taken their full dose for 48 weeks. Assessing the impact of taking the full dose is not trivial; clearly the ITT approach underestimates the response, whereas subsetting the patients who took a large majority of their full dose (eg, 80% of the total dose) likely overestimates the response. Using methodology developed by Efron and Feldman (I), we develop a statistical model that incorporates compliance as a covariate, thereby allowing for an estimate of the fully compliant response rate. It is estimated that the treatment benefit as measured by the difference in sustained virologic response rates of I/R versus UP at full compliance ranged from 23% to 26% compared to 20% for the ITT analysis and 27% for the 80% compliant subgroup.
Similar content being viewed by others
References
Efron B, Feldman D. Compliance as an explanatory variable in clinical trials (with discussion). J Am Stat Assoc. 1991;86:9–26.
Alter MJ. Epidemiology of hepatitis C. Hepatol. 1997;26:62S–65S.
Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis: effects of dose and duration. Hepatol. 1996;24:778–789.
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with Ribavirin as initial treatment for chronic hepatitis C. New Engl J Med. 1998;339:1485–1492.
Poynard T, Marcellin P, Lee SS, et al. Randomised trial of Interferon alpha-2b plus Ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352: 1426–1432.
Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clinical Pharmacol Therapeutics. 1995;57:6–15.
Heitjan DF. Ignorability and bias in clinical trials. Stat Med. 1999;18:2421–2434.
Pocock SJ, Abdalla M. The hope and the hazards of using compliance data in randomized controlled trials. Stat Med. 1998;17:303–317.
Lipid Research Clinic Program. The lipid research clinics coronary primary prevention trial results, Parts I and II. JAMA. 1984;251:351–374.
McCullagh P, Neider JA. Generalized Linear Models. 2nd Edition. London: Chapman & Hall/CRC; 1989.
Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Education Psychol. 1974;66:658–701.
Holland P. Statistics and causal inference (with discussion). J Am Stat Assoc. 1986;81:945–970.
Hastie TJ, Tibshirani RJ. Generalized Additive Models. London: Chapman & Hall/CRC; 1990.
Knight K. Mathematical Statistics. London: Chapman & Hall/CRC; 2000.
Chambers JM, Hastie TJ. Statistical Models in S. London: Chapman & Hall; 1991.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mak, C., Heft, S.M., Amkraut, H. et al. Compliance as an Explanatory Variable in Hepatitis-C. Ther Innov Regul Sci 35, 1351–1361 (2001). https://doi.org/10.1177/009286150103500431
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150103500431